Please try another search
For the nine months ended 31 March 2021, Exmceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased 6% to C$6.4M. Higher net loss reflects Share-based compensation increase from C$621K to C$4.1M (expense), Gain on settlement of loans payable decrease from C$108K (income) to C$0K, Interest expense increase of 8% to C$437K (expense).
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -2.4 | -3.48 | -1.85 | -3.62 |
Net Income | -2.43 | -3.93 | -2.23 | -3.26 |
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Total Assets | 1.27 | 1.13 | 1.51 | 1.25 |
Total Liabilities | 2.89 | 2.53 | 2.36 | 8.14 |
Total Equity | -1.62 | -1.4 | -0.85 | -6.88 |
Period Ending: | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -1.33 | -0.99 | -0.63 | -3.36 |
Cash From Investing Activities | -0.02 | -0.03 | -0.03 | -1.1 |
Cash From Financing Activities | 1.29 | 0.91 | 0.91 | 4.58 |
Net Change in Cash | 0.08 | -0.06 | 0.26 | 0.12 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review